DDInter336 DDInter1626
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998. Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer cells that lack a DNA repair mechanism, rucaparib causes cancer cell death and reduces tumour growth.[A18745,A31354] Rucaparib was granted FDA Breakthrough Therapy designation in April 2015 and accelerated approval in December 2016. The drug was later approved by the European Commission in May 2018. It is currently used to treat recurrent ovarian and prostate cancer in adults.[L42155,L42185]
Celecoxib {u} (Compound) resembles {v} (Compound) Sulfaphenazole
Sulfaphenazole {u} (Compound) resembles {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Celecoxib {u} (Compound) resembles {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Vemurafenib
Vemurafenib {u} may lead to a major life threatening interaction when taken with {v} Rucaparib
Celecoxib {u} (Compound) resembles {v} (Compound) Sulfaphenazole
Sulfaphenazole {u} (Compound) resembles {v} (Compound) Dapsone
Dapsone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Celecoxib {u} (Compound) binds {v} (Gene) CA14
CA14 {u} (Gene) is bound by {v} (Compound) Nilotinib
Nilotinib {u} may lead to a major life threatening interaction when taken with {v} Rucaparib
Celecoxib {u} (Compound) binds {v} (Gene) CA12
CA12 {u} (Gene) is bound by {v} (Compound) Imatinib
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Celecoxib {u} (Compound) binds {v} (Gene) ALB
ALB {u} (Gene) is bound by {v} (Compound) Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Rucaparib
Celecoxib {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Methotrexate
Methotrexate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Celecoxib {u} (Compound) upregulates {v} (Gene) ST3GAL5
ST3GAL5 {u} (Gene) is upregulated by {v} (Compound) Perphenazine
Perphenazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Celecoxib {u} (Compound) upregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is upregulated by {v} (Compound) Escitalopram
Escitalopram {u} may lead to a major life threatening interaction when taken with {v} Rucaparib
Celecoxib {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Etoposide
Etoposide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Celecoxib (Compound) resembles Sulfaphenazole (Compound) and Sulfaphenazole (Compound) resembles Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Celecoxib (Compound) resembles Etoricoxib (Compound) and Etoricoxib (Compound) resembles Vemurafenib (Compound) and Vemurafenib may lead to a major life threatening interaction when taken with Rucaparib
Celecoxib (Compound) resembles Sulfaphenazole (Compound) and Sulfaphenazole (Compound) resembles Dapsone (Compound) and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Celecoxib (Compound) binds CA14 (Gene) and CA14 (Gene) is bound by Nilotinib (Compound) and Nilotinib may lead to a major life threatening interaction when taken with Rucaparib
Celecoxib (Compound) binds CA12 (Gene) and CA12 (Gene) is bound by Imatinib (Compound) and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Celecoxib (Compound) binds ALB (Gene) and ALB (Gene) is bound by Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Celecoxib (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Methotrexate (Compound) and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Celecoxib (Compound) upregulates ST3GAL5 (Gene) and ST3GAL5 (Gene) is upregulated by Perphenazine (Compound) and Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Celecoxib (Compound) upregulates RRS1 (Gene) and RRS1 (Gene) is upregulated by Escitalopram (Compound) and Escitalopram may lead to a major life threatening interaction when taken with Rucaparib
Celecoxib (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is bound by Etoposide (Compound) and PTGS2 (Gene) is upregulated by Etoposide (Compound) and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib